SVRA.O (SVRA.O) News
Follow SVRA.O (SVRA.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Savara to present new IMPALA trial analysis of molgramostim in aPAP at CHEST 2026
Savara flagged new analyses of molgramostim from its IMPALA and IMPALA-2 trials in autoimmune pulmonary alveolar proteinosis for presentation at CHEST 2026. Long-term IMPALA-2 open-label data will be presented in the fut
NEWS | Oct 12, 2026, 08:06 PM UTC
H
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long — Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
For best results when printing this announcement, please click on link below: Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune
NEWS | Oct 12, 2026, 08:05 PM UTC